Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.

@article{Jia2015DirectEO,
  title={Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.},
  author={Jingquan Jia and Andrew Dellinger and Eric S. Weiss and Anuradha Bulusu and Christel Rushing and Haiyan Li and Leigh Ann Howard and Neal Kaplan and Herbert H Pang and Herbert I. Hurwitz and Andrew B. Nixon},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2015},
  volume={21 15},
  pages={3442-52}
}
PURPOSE In early clinical testing, most novel targeted anticancer therapies have limited toxicities and limited efficacy, which complicates dose and schedule selection for these agents. Confirmation of target inhibition is critical for rational drug development; however, repeated tumor biopsies are often impractical and peripheral blood mononuclear cells… CONTINUE READING